Bazelet Research began advanced plant breeding efforts and late-stage cultivar development. "Our breeding efforts will create new THC-Free cannabis cultivars particularly for local and regional adaptation to soils and climates of the Southeast U.S," Bazelet team explains. "The primary goal is the Company releasing safe, effective 0.00% THC cultivars that are publicly available in the legal US hemp industry."
Bazelet Research will develop new THC-Free cannabis plant varieties that help create or meet emerging demand for new agriculturally based industrial and food products including plant-based chemicals that have industrial and/or pharmaceutical relevance.
"Cannabis breeding for years has used questionable techniques that over years have led most marketplace genetics focused on producing THC. The Company's unique heirloom, landrace genetics, a 15,000sf plant tissue culture laboratory, CRISPR Gene-Editing / Genomic Sequencing Technology, over 70 years in the plant industry, and more than 60 highly trained employees prepared to conduct this valuable scientific research. Our new plant varieties are 0.00% THC plants that will offer higher yields, better drought, and pest resistance, and selectively express specific genes allowing our growers to produce unique higher-value crops," said David Grand, Bazelet co-founder, and Chief Research Officer. He further said, "We will pinpoint correlations between the genetic effects of certain strains for their optimal medicinal, consumer, and industrial application."
For more information:
Bazelet Research
Kirk Calvert
(321) 558-2170
[email protected]
bazelethealth.com